Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1

Conditions

Tinnitus 1Ototoxicity 1Lung Neoplasms 1Hearing Loss 1Head and Neck Neoplasms 1Deafness 1

Interventions

pembrolizumab 27Cisplatin 18Cetuximab 12Carboplatin 12Surveys and Questionnaires 8Radiotherapy 8Paclitaxel 8Docetaxel 6Radiotherapy, Intensity-Modulated 5Surgical Procedures, Operative 4dostarlimab 3Therapeutics 3Standard of Care 3Fluorouracil 3Cyclophosphamide 3Chemoradiotherapy 3Blood Specimen Collection 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3toripalimab 2nimotuzumab 2fludarabine 2durvalumab 2atezolizumab 2abemaciclib 2X-Rays 2Taxes 2Radiosurgery 2Radiation 2Nivolumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × ebselen × 90 days × Clear all
NCT01451853 2026-06-03

SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss

Sound Pharmaceuticals, Incorporated

Phase 2 Withdrawn
Head & NeckThoracic

Ototoxicity, Deafness, Head and Neck Neoplasms, Lung Neoplasms, Tinnitus, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡